READDI, Inc.
READDI is a nonprofit biotechnology company dedicated to proactively developing safe and effective broad-spectrum antiviral drugs before the next pandemic. It aims to prevent global health crises by leveraging academia, industry, and government expertise to discover and develop medicines that can be deployed immediately at the onset of future pandemics. READDI's mission is to ensure that broad-spectrum small molecule antivirals are ready for immediate use, targeting virus families most likely to cause outbreaks, and making effective antivirals accessible worldwide.
Industries
Products
Portfolio of broad‑spectrum small‑molecule antiviral candidates
A prospective pipeline of orally available small‑molecule antiviral candidates targeted at high‑risk virus families, advanced to varying preclinical and clinical readiness stages.
Small‑molecule antiviral landscape database
A curated database that catalogs small‑molecule antiviral programs (including abandoned assets) with fields for mechanism, class, indications and development stage to inform prioritization and repurposing decisions.
Portfolio of broad‑spectrum small‑molecule antiviral candidates
A prospective pipeline of orally available small‑molecule antiviral candidates targeted at high‑risk virus families, advanced to varying preclinical and clinical readiness stages.
Small‑molecule antiviral landscape database
A curated database that catalogs small‑molecule antiviral programs (including abandoned assets) with fields for mechanism, class, indications and development stage to inform prioritization and repurposing decisions.
Services
Collaborative antiviral discovery and development partnerships
Joint programs with academic, industry and government partners to discover, optimize and advance broad‑spectrum small‑molecule antivirals.
Antiviral pipeline assessment and database services
Creation and maintenance of a comprehensive small‑molecule antiviral landscape database to support pipeline mapping, gap analysis and prioritization of development opportunities.
Clinical trial design and preparedness consulting
Preparation of Phase II/III randomized clinical trial designs and associated readiness activities to enable rapid initiation of efficacy trials during outbreaks.
Manufacturing partner identification and readiness planning
Advance identification of manufacturing partners and development of manufacturing plans to support rapid scale‑up and distribution of small‑molecule antivirals.
Collaborative antiviral discovery and development partnerships
Joint programs with academic, industry and government partners to discover, optimize and advance broad‑spectrum small‑molecule antivirals.
Antiviral pipeline assessment and database services
Creation and maintenance of a comprehensive small‑molecule antiviral landscape database to support pipeline mapping, gap analysis and prioritization of development opportunities.
Clinical trial design and preparedness consulting
Preparation of Phase II/III randomized clinical trial designs and associated readiness activities to enable rapid initiation of efficacy trials during outbreaks.
Manufacturing partner identification and readiness planning
Advance identification of manufacturing partners and development of manufacturing plans to support rapid scale‑up and distribution of small‑molecule antivirals.
Expertise Areas
- Antiviral drug discovery
- Broad‑spectrum small‑molecule therapeutics
- Medicinal chemistry and lead optimization
- Virology and viral target biology
Key Technologies
- Small‑molecule therapeutics
- Broad‑spectrum antiviral target strategies
- Medicinal chemistry
- AI and machine‑learning for drug discovery